Targeting mitochondrial dysfunction in the treatment of heart failure

References

• Centers for Disease Control A. Heart disease facts [ cited 2016 May 13]. Available from: http://www.cdc.gov/heartdisease/facts.htm.
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:143–152.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–944.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control B. Heart failure fact sheet [ cited 2016 May 18]. Available from: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm.
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al.; Writing Group Members; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133:447–454.
   PubMed Web of Science ®Google Scholar
• Spinarova L, Vitovec J. Neurohumoral changes in chronic heart failure. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151:201–207.
   PubMedGoogle Scholar
• Buglioni A, Burnett JC Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015;443:3–8.
   PubMed Web of Science ®Google Scholar
• Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc. 2010;85:180–195.
   PubMed Web of Science ®Google Scholar
• Chinnery PF. Mitochondrial disease in adults: what’s old and what’s new? EMBO Mol Med. 2015;7:1503–1512.
   PubMed Web of Science ®Google Scholar
• Payne BA, Chinnery PF. Mitochondrial dysfunction in aging: much progress but many unresolved questions. Biochim Biophys Acta. 2015;1847:1347–1353.
   PubMed Web of Science ®Google Scholar
• Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th ed. New York (NY): WH Freeman; 2002.
   Google Scholar
• Moreno-Lastres D, Fontanesi F, García-Consuegra I, et al. Mitochondrial complex I plays an essential role in human respirasome assembly. Cell Metab. 2012;15:324–335.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Sharov V, Riddle JM, et al. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1992;24:1333–1347.
   PubMed Web of Science ®Google Scholar
• Okonko DO, Shah AM. Heart failure: mitochondrial dysfunction and oxidative stress in CHF. Nat Rev Cardiol. 2015;12:6–8.
   PubMed Web of Science ®Google Scholar
• Rosca MG, Vazquez EJ, Kerner J, et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res. 2008;80:30–39.
   PubMed Web of Science ®Google Scholar
• Barrientos A, Ugalde C. I function, therefore I am: overcoming skepticism about mitochondrial supercomplexes. Cell Metab. 2013;18:147–149.
   PubMed Web of Science ®Google Scholar
• Ott M, Robertson JD, Gogvadze V, et al. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA. 2002;99:1259−1263.
   PubMed Web of Science ®Google Scholar
• Zhang M, Mileykovskaya E, Dowhan W. Gluing the respiratory chain together: cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J Biol Chem. 2002;277:43553–43556.
   PubMed Web of Science ®Google Scholar
• Gohil VM, Hayes P, Matsuyama S, et al. Cardiolipin biosynthesis and mitochondrial respiratory chain function are interdependent. J Biol Chem. 2004;279:42612–42618.
   PubMed Web of Science ®Google Scholar
• Walker JE. The ATP synthase: the understood, the uncertain and the unknown. Biochem Soc Trans. 2013;41:1–16.
   PubMed Web of Science ®Google Scholar
• Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrial pharmaceutics in cardiovascular diseases. World J Cardiol. 2014;6:1091–1099.
   PubMedGoogle Scholar
• Shen Z, Ye C, McCain K, et al. The role of cardiolipin in cardiovascular health. Biomed Res Int. 2015;2015:891707.
   PubMed Web of Science ®Google Scholar
• Sharov VG, Goussev A, Lesch M, et al. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1998;30:1757–1762.
   PubMed Web of Science ®Google Scholar
• Sharov VG, Todor AV, Silverman N, et al. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol. 2000;32:2361–2367.
   PubMed Web of Science ®Google Scholar
• Lai L, Leone TC, Zechner C, et al. Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev. 2008;22:1948–1961.
   PubMed Web of Science ®Google Scholar
• Martin OJ, Lai L, Soundarapandian MM, et al. A role for peroxisome proliferator-activated receptor γ coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ Res. 2014;114:626–636.
   PubMed Web of Science ®Google Scholar
• Gupta RC, Szekely K, Wang M, et al. Long-term therapy with partial adenosine A1 receptor agonist capadenoson, improves peroxisome proliferators-activated receptor coactivator-1α phosphorylation and protein expression in left ventricular myocardium of dogs with chronic heart failure. J Am Coll Cardiol. 2013;61(10–S):E702.
   Google Scholar
• Latronico MV, Condorelli G. The might of microRNA in mitochondria. Circ Res. 2012;110:1540–1542.
   PubMed Web of Science ®Google Scholar
• Ong SB, Kalkhoran SB, Cabrera-Fuentes HA, et al. Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease. Eur J Pharmacol. 2015;763:104–114.
   PubMed Web of Science ®Google Scholar
• Song M, Mihara K, Chen Y, et al. Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts. Cell Metab. 2015;21:273–285.
   PubMed Web of Science ®Google Scholar
• Wai T, García-Prieto J, Baker MJ, et al. Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science. 2015;350:aad0116.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Gupta RC, Rastogi S, et al. Dysregulation of mitochondria fission and fusion proteins in explanted failure human hearts. J Heart Lung Transplant. 2011;30(4S):S137.
   Google Scholar
• Sabbah HN, Gupta RC, Szekely K, et al. Bendavia (MTP-131), a mitochondria targeting peptide, normalizes dysregulation of mitochondria fission and fusion proteins in myocardium of dogs with chronic heart failure. Circulation. 2014;130:A12903.
   Google Scholar
• Song M, Chen Y, Gong G, et al. Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res. 2014;115:348–353.
   PubMed Web of Science ®Google Scholar
• Sharov VG, Todor AV, Imai M, et al. Inhibition of mitochondrial permeability transition pores by cyclosporine A improves cytochrome c oxidase function and increases rate of ATP synthesis in failing cardiomyocytes. Heart Fail Rev. 2005;10:305–310.
   PubMed Web of Science ®Google Scholar
• Sharov VG, Todor A, Khanal S, et al. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol. 2007;42:150–158.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9:e002206.
   PubMed Web of Science ®Google Scholar
• Bayeva M, Sawicki KT, Butler J, et al. Molecular and cellular basis of viable dysfunctional myocardium. Circ Heart Fail. 2014;7:680–691.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Shirakabe A, Brady C, et al. Molecular mechanisms mediating mitochondrial dynamics and mitophagy and their functional roles in the cardiovascular system. J Mol Cell Cardiol. 2015;78:116–122.
   PubMed Web of Science ®Google Scholar
• Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013;113:709–724.
   PubMed Web of Science ®Google Scholar
• Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res. 2000;45:704–712.
   PubMed Web of Science ®Google Scholar
• Goussev A, Sharov VG, Shimoyama H, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275(2 Pt 2):H626–631.
   Google Scholar
• Knowlton AA, Chen L, Malik ZA. Heart failure and mitochondrial dysfunction: the role of mitochondrial fission/fusion abnormalities and new therapeutic strategies. J Cardiovasc Pharmacol. 2014;63:196–206.
   PubMed Web of Science ®Google Scholar
• Pei H, Yang Y, Zhao H, et al. The role of mitochondrial functional proteins in ROS production in ischemic heart diseases. Oxid Med Cell Longev. 2016;2016:5470457.
   PubMed Web of Science ®Google Scholar
• Zalewski J, Claus P, Bogaert J, et al. Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion. Basic Res Cardiol. 2015;110:18.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail. 2013;6:563–571.
   PubMed Web of Science ®Google Scholar
• Akbar M, Okajima F, Tomura H, et al. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol. 1994;45:1036–1042.
   PubMed Web of Science ®Google Scholar
• Yuan K, Cao C, Han JH, et al. Adenosine stimulated atrial natriuretic peptide release through A1 receptor subtype. Hypertension. 2005;46:1381–1387.
   PubMed Web of Science ®Google Scholar
• Martynyuk AE, Kane KA, Cobbe SM, et al. Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Pflugers Arch. 1996;431:452–457.
   PubMed Web of Science ®Google Scholar
• Kitakaze M, Hori M, Takashima S, et al. Ischemic preconditioning increases adenosine release and 50-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation. 1993;87:208–215.
   PubMed Web of Science ®Google Scholar
• Shneyvays V, Mamedova LK, Leshem D, et al. Insights into the cardioprotective function of adenosine A(1) and A(3) receptors. Exp Clin Cardiol. 2002;7:138–145.
   PubMedGoogle Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552.
   PubMed Web of Science ®Google Scholar
• Nell PG, Albrecht-Küpper B. The adenosine A1 receptor and its ligands. Prog Med Chem. 2009;47:163–201.
   PubMedGoogle Scholar
• Albrecht-Küpper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8(Suppl 1):91–99.
   PubMed Web of Science ®Google Scholar
• Birk AV, Chao WM, Bracken C, et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171:2017–2028.
   PubMed Web of Science ®Google Scholar
• Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96:672−683.
   PubMed Web of Science ®Google Scholar
• Daubert MA, Yow E, Dunn G, et al. Effects of a novel tetrapeptide in heart failure with reduced ejection fraction: a phase I randomized, placebo-controlled trial of elamipretide. J Am Coll Cardiol. 2016;67(13S):1283–1283.
   Google Scholar